DelMar Pharma reports updated results on from phase 2 clinical trial of VAL-083
DelMar Pharmaceuticals provided an update on the first 20 patients enrolled in its ongoing Phase 2 clinical study investigating the first-line treatment of VAL-083 in combination with radiation therapy in newly-diagnosed, MGMT-unmethylated GBM. August 13, 2019